期刊文献+

早期应用双膦酸盐在老年非小细胞肺癌治疗中的作用

下载PDF
导出
摘要 目的 探讨早期静脉应用双膦酸盐在老年非小细胞肺癌(NSCLC)治疗中的作用。方法 对照研究中国石油中心医院住院治疗的老年NSCLC患者68例,将骨密度(BMD)T-Score≤-2.5作为双膦酸盐应用指征,在确诊骨转移之前即开始应用双膦酸盐定义为早期应用。按是否早期应用双膦酸盐,将68例患者按照临床分期分为两组,早期应用双膦酸盐患者34例为治疗组;未早期应用者34例为对照组。比较两组骨转移发生率及确诊时间。结果 治疗组骨转移发生率47.06%(16/34),对照组82.35%(28/34),二者差异显著(χ2=9.27,P〈0.01);治疗组中位骨转移发生时间较对照组延迟87(218 vs 131)d,二者差异显著(P=0.006)。结论 早期应用双膦酸盐治疗经老年NSCLC患者,可以减少骨转移发生率,并推迟骨转移发生时间。
出处 《中国老年学杂志》 CAS CSCD 北大核心 2016年第20期5066-5067,共2页 Chinese Journal of Gerontology
基金 廊坊市科学技术研究与发展计划项(2012013080)
  • 相关文献

参考文献11

  • 1Isla D,Afonso R,Bosch-Barrera J,et al.Zoledronic acid in lung cancer with bone metastases:a review[J].Expert Rev Anticancer Ther,2013;13(4):421-6.
  • 2Rossi A,Gridelli C,Ricciardi S,et al.Bone metastases and non-small cell lung cancer:from bisphosfonates to targeted therapy[J].Curr Med Chem,2012;19(32):5524-35.
  • 3Brodowicz T,O'Byrne K,Manegold C.Bone matters in lung cancer[J].Ann Oncol,2012;23(9):2215-22.
  • 4杜宝昌,刘军,王帅兵,郭茜.早期应用双膦酸盐在晚期恶性肿瘤治疗中的作用[J].肿瘤学杂志,2014,20(5):406-408. 被引量:2
  • 5杜宝昌,刘军,王帅兵,齐秀恒,邹庆华.早期应用双磷酸盐在晚期前列腺癌治疗中的作用[J].中国肿瘤,2014,23(10):878-881. 被引量:5
  • 6王帅兵,杜宝昌,刘军,齐秀恒,邹庆华,杨晓红.早期应用双膦酸盐治疗乳腺癌骨转移患者21例[J].实用医学杂志,2014,30(7):1147-1150. 被引量:10
  • 7Hagiwara M,Delea TE,Cong Z,et al.Utilization of intravenous bisphosphonates in patients with bone metastases secondary to breast,lung,or prostate cancer[J].Supp Care Cancer,2014;22(1):103-13.
  • 8Tolia M,Zygogianni A,Kouvaris JR,et al.The key role of bisphosphonates in the supportive care of cancer patients[J].Anticancer Res,2014;34(1):23-37.
  • 9Coleman R,Body JJ,Aapro M,et al.Bone health in cancer patients:ESMO Clinical Practice Guidelines[J].Ann Oncol,2014;25(1):1-14.
  • 10Hirsh V.Bisphosphonates in lung cancer:can they provide benefits beyond prevention of skeletal morbidity[J]?Anticancer Agents Med Chem,2012;12(2):137-43.

二级参考文献32

  • 1Trinkaus M, Simmons C, Myers J, et al. Skeletal-related events (SREs) in breast cancer patients with bone metastases treated in the nontrial setting [J]. Support Care Cancer, 2010, 18 (2), 197-203.
  • 2Henk HJ, Kaura S. Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in women with breast cancer and bone metastasis in a managed care plan [J]. J Med Econ,2012,15(1) : 175-184.
  • 3Woodward JK, Neville-Webbe HL, Coleman RE, et al. Combined effects of zoledronic acid and doxorubicin on breast cancer cell invasion in vitro [J]. Anticancer Drugs, 2005,16 (8) : 845-854.
  • 4Green JR. Antitumor effects of bisphosphonates [J]. Cancer, 2003,97(3 Suppl) : 840-847.
  • 5Vincenzi B, Santini D, Dieuonzo G, et al. Zoledronic acid related angiogenesis modifications and survival in advanced breast cancer patients [ J ]. J Interferon Cytokine Res, 2005,25 (3) : 144-151.
  • 6Duivenvoorden WC, Vukmirovic-Popovie S, Kalina M, et al. Effect of Zoledronic acid on the doxyeycline-induced decrease in tumor burden in a bone metastasis model of human breast cancer [ J ]. Br J Cancer, 2007,96 (10) : 1526-1531.
  • 7Aft R, Naughton M, Trinkaus K, et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial [J]. Lancet Oncol, 2010, 11 (5) : 421-428.
  • 8Gnant M, Mlineritseh B, Stoeger H, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early- stage breast eancer:62-month follow-up from the ABCSG-12 randomised trial [J]. Lancet Oneol, 2011,12(7) :631-641.
  • 9Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase Ⅲ, double-blind, comparative trial [J]. Cancer J, 2001,7 (7) : 377-387.
  • 10Henk HJ, Kaura S. Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in women with breast cancer and bone metastasis in a managed care plan [J]. J Med Econ ,2012,15( 1 ) : 175-184.

共引文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部